<DOC>
	<DOC>NCT01722604</DOC>
	<brief_summary>The main purpose of this prospective study is to demonstrate the therapeutic equivalence of topical brinzolamide dosed three times daily compared with AzoptTM (brinzolamide ophthalmic suspension 1%) dosed three times daily in IOP reduction in patients with POAG or OH.</brief_summary>
	<brief_title>Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Brinzolamide</mesh_term>
	<criteria>Male and females 18 years of age or older, diagnosed with primary openangle glaucoma or ocular hypertension. Patients with any form of glaucoma (such as secondary, congenital, juvenile or normal tension glaucoma, angle closure glaucoma) in either eye other than primary openangle glaucoma, ocular hypertension.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>